Whereas no correlation of paxillin expression with ER, PR and HER2 status in imprint smears of aggressive breast cancers was found (17), Short et al provided evidence that paxillin is overexpressed in 28% of breast cancers, and that this correlates with HER2 status (18). This evidence concerns the gene ERBB2 and breast carcinoma.